DPD for 5-fluorouracil toxicity
Fluoropyrimidines (5-fluorouracil, capecitabine and tegafur) are chemotherapy drugs used to treat certain cancers. Treatment with fluoropyrimidines is generally well tolerated. However, 3-6% of patients suffer serious adverse drug reactions as a result of genetic variation in their DPYD gene which means they are unable to properly metabolise and breakdown these drugs. Genetic testing for the common DPYD genetic variants is recommended in some cancer patients. Although the test does not remove all treatment risk, it does reduce the incidence of toxicity.
Currently testing for patients in the East GLH region will be performed by the Purine Research Laboratory in Biochemical Sciences lab at St Thomas’ Hospital, London.
To ensure a rapid service, submit samples directly to the Viapath Purine Laboratory by first class post or courier.
For more information: